Comparative Pharmacology
Head-to-head clinical analysis: TEMOZOLOMIDE versus TEPYLUTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TEMOZOLOMIDE versus TEPYLUTE.
TEMOZOLOMIDE vs TEPYLUTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Temozolomide is an alkylating agent that causes DNA methylation at O6 and N7 positions of guanine, leading to DNA damage and apoptosis. It is converted to the active metabolite MTIC under physiological conditions.
Progestin that transforms endometrium from proliferative to secretory phase, inhibits gonadotropin secretion, and increases cervical mucus viscosity.
150 mg/m2 orally once daily for 5 consecutive days of a 28-day cycle; for first cycle, then increase to 200 mg/m2/day if tolerated.
100 mg orally once daily
None Documented
None Documented
1.8 hours (range 1.3–2.5 hours) for temozolomide; the active monomethyl triazeno imidazole carboxamide (MTIC) metabolite has a half-life of approximately 2.0 hours.
Clinical Note
moderateTemozolomide + Digoxin
"Temozolomide may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTemozolomide + Digitoxin
"Temozolomide may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateTemozolomide + Deslanoside
"Temozolomide may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateTemozolomide + Acetyldigitoxin
"Temozolomide may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 10-15 hours in severe renal impairment.
Approximately 38% of total radioactivity is excreted in urine over 7 days (5.6% as unchanged temozolomide, 12% as AIC metabolite, 21% as other polar metabolites), and less than 1% is excreted in feces.
Primarily renal (70-80% unchanged) and fecal (15-20% as metabolites).
Category D/X
Category C
Alkylating Agent
Alkylating Agent